Letters to the Editor

Chronic Use of Echinacea Should Be Discouraged

TO THE EDITOR: Dr. Kligler's review¹ of echinacea was comprehensive, concise, and effectively summarized the evidence behind the popular herb.¹ His review commented that there are no reported drug interactions with the use of echinacea. Although there are no reports of any significant drug interactions with echinacea, it has been suggested that use of echinacea for more than eight weeks could cause hepatotoxicity; therefore, echinacea should not be used with other known hepatotoxic drugs such as amiodarone, methotrexate, and ketoconazole.² Even the concurrent use of acetaminophen and echinacea may cause an increase in the incidence of hepatotoxicity.³ This is particularly important because echinacea and acetaminophen are frequently used to treat the symptoms of the common cold.

Also, in contrast to the acute immunostimulatory effects of echinacea, long-term use of echinacea (more than eight weeks) is accompanied by the potential for immunosuppression.⁴ This could be one factor to explain why past studies investigating the use of echinacea for the prevention of colds failed to show any benefits, because in the majority of trials enrolled subjects took echinacea for more than eight weeks.

In my opinion, the use of echinacea should be restricted to a maximum of two weeks for acute illness. I believe that the chronic use of echinacea should be discouraged because its use in the prevention of colds has not been proved beneficial, can lead to increased risk of hepatotoxicity, and may have the potential for immunosuppression. Even though echinacea does not have any documented drug interactions, we must be vigilant in monitoring for potential interactions and adverse effects.

DOSON CHUA, PHARM.D.
St. Michael's Hospital
300 Bond St.
Toronto, Ontario M5B 1W8 Canada

REFERENCES

1. Kligler B. Echinacea. Am Fam Physician 2003;67: 77-80.
2. Miller LG. Herbal medicines: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158: 2200-11.
3. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002;27:391-401.
4. Boullata JI, Nace AM. Safety issues with herbal medicine. Pharmacotherapy 2000;20:257-69.

IN REPLY: I agree with Dr. Chua that the long-term use of echinacea should be discouraged based on the fact that there is no evidence that such use is effective in the prevention of upper respiratory illness. However, regarding the issue of hepatotoxicity and echinacea, evidence is lacking. The initial concerns regarding hepatotoxicity with long-term use of echinacea arose from the presence of alkaloids in the pyrrolizidine family in certain parts of the echinacea plant. Pyrrolizidine alkaloids with an unsaturated nucleus, such as those found in comfrey, are known to be hepatotoxic with long-term use. However, the pyrrolizidine alkaloids found in echinacea, isotussilagine and tussilagine, possess a saturated nucleus.¹ Currently, this category of pyrrolizidines has not been found to be hepatotoxic. Thus, I feel that Dr. Chua's advice to discourage the concurrent use of acetaminophen and echinacea is not based on current evidence and may lead to unwarranted concerns for physicians and patients regarding the use of this herb. It also is notable that there have been no published reports of significant hepatotoxicity with echinacea, despite its widespread use.

BENJAMIN KLIGLER, M.D., M.P.H.
Beth Israel Center for Health and Healing
245 Fifth Ave.
New York, NY 10016

REFERENCES

1. Newall CA, Anderson LA, Phillipson JD. Herbal medicines: a guide for health-care professionals. London: Pharmaceutical Press, 1996.

Send letters to Jay Siwek, M.D., Editor, American Family Physician, 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2672; fax: 913-906-6080; e-mail: afplet@aafp.org. Please include your complete address, telephone number, and fax number. Letters should be submitted on disk, double-spaced, fewer than 500 words, and limited to one table or figure and six references. Please submit a word count. Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.